Loading
Life sciences · Journal article
Medcomm · October 29, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
ABSTRACT Gastric cancer is a multifactorial disease shaped by diverse risk factors and a complex pathogenesis spanning from chronic atrophic gastritis to invasive malignancy. Its global incidence shows marked geographic disparities, and advances in understanding its pathogenic mechanisms have improved diagnosis and treatment. Although the relationship between gastric cancer and macrophages has been extensively investigated, a systematic review integrating the entire clinical and biological continuum of gastric cancer, from epidemiology to management, with a focus on macrophages remains lacking. This review summarizes the epidemiology and multidimensional risk factors for gastric cancer, including infectious, dietary, genetic, microbiome, and metabolite‐related factors. We describe the evolution of precancerous conditions, molecular alterations such as miRNA expression, and the bidirectional interactions between gastric cancer cells and macrophages that drive tumor progression within the tumor microenvironment. We also review clinical features, diagnostic approaches based on screening and endoscopy, and current management strategies, including surgery, systemic therapies, targeted therapies, immunotherapy, macrophage‐targeted therapies, macrophage metabolic reprogramming, and recent preclinical and clinical advances. Overall, this review integrates evidence from epidemiology, molecular biology, immunology, and pathology to provide a comprehensive framework for understanding gastric cancer pathogenesis and current as well as emerging therapeutic strategies.